EGFR Inhibitors-Induced Skin Disorders Market Size in the 7MM is expected to increase at a significant CAGR by 2034, estimates DelveInsight

DelveInsight's "EGFR Inhibitors-Induced Skin Disorders Market Insights, Epidemiology, and Market Forecast- 2034 report offers an in-depth understanding of the EGFR Inhibitors-Induced Skin Disorders, historical and forecasted epidemiology as well as the EGFR Inhibitors-Induced Skin Disorders market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover Key Insights into the EGFR Inhibitors-Induced Skin Disorders Market with DelveInsight's In-Depth Report @ EGFR Inhibitors-Induced Skin Disorders Market Size [https://www.delveinsight.com/sample-request/egfr-inhibitors-induced-skin-disorders-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the EGFR Inhibitors-Induced Skin Disorders Market Report

* EGFR is altered in 3.22% of colorectal carcinoma patients with EGFR mutation present in 2.33% of all colorectal carcinoma patients.
* Nearly 20% of patients are affected with EGFR mutation in NSCLC.
* In pancreatic ductal carcinoma, EGFR is overexpressed in 30-89% of the cases.
* In 2023, there were more than 30,000 treatable incident cases of EGFR inhibitors in the United States.
* The leading EGFR Inhibitors-Induced Skin Disorders Companies such as AstraZeneca, Pfizer, Novartis Pharmaceuticals, Janssen Research & Development, Yuhan Corporation, Takeda , and many others.
* Promising EGFR Inhibitors-Induced Skin Disorders Therapies such as LUT-014, HT-001, AC-701 Topical Gel 0.3%, and others

Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful EGFR Inhibitors-Induced Skin Disorders Market Forecast @ EGFR Inhibitors-Induced Skin Disorders Treatment Market [https://www.delveinsight.com/sample-request/egfr-inhibitors-induced-skin-disorders-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

EGFR Inhibitors-Induced Skin Disorders Epidemiology Segmentation in the 7MM

* Total Prevalence of EGFR Inhibitors-Induced Skin Disorders
* Prevalent Cases of EGFR Inhibitors-Induced Skin Disorders by severity
* Gender-specific Prevalence of EGFR Inhibitors-Induced Skin Disorders
* Diagnosed Cases of Episodic and Chronic EGFR Inhibitors-Induced Skin Disorders

Download the Report to understand which factors are driving EGFR Inhibitors-Induced Skin Disorders epidemiology trends @ EGFR Inhibitors-Induced Skin Disorders Prevalence [https://www.delveinsight.com/sample-request/egfr-inhibitors-induced-skin-disorders-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

EGFR Inhibitors-Induced Skin Disorders Emerging Drugs

* LUT014: Lutris Pharma

LUT014 is a topical B-RAF inhibitor, first-in-class, small molecule. Lutris Pharma is conducting a Phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of LUT014 in metastatic colorectal cancer patients with EGFR Inhibitors-induced acneiform lesions. The Phase I study demonstrated the first evidence of treatment effectiveness by reducing the severity of acneiform lesions and improving patient quality of life. Promising preliminary data from the Phase II study may point to a dose-response and the high dose success rate achieved demonstrates the efficacy of LUT014.

* HT-001: Hoth Therapeutics

It is a topical formulation being developed by Hoth Therapeutics and is currently under development to treat patients with mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor inhibitor therapy. The Phase IIa CLEER clinical trial is currently underway to evaluate the safety and efficacy of HT-001 in patients with rash and skin disorders associated with EGFR inhibitor therapy. In January 2023, the US FDA accepted an IND application for HT-001 for the treatment of rash and skin disorders associated with EGFR inhibitor therapy.

EGFR Inhibitors-Induced Skin Disorders Drugs Market Insights

The drug chapter segment of the EGFR Inhibitors Induced Skin Disorders report encloses a detailed analysis of the late-stage (Phase III) and mid-stage (Phase II/III and Phase II) pipeline drugs. The current key players include Lutris Pharma (LUT014), Hoth Therapeutics (HT-001), and others. The drug chapter also helps understand the EGFR Inhibitors-Induced Skin Disorders clinical trial details, pharmacological action, agreements and collaborations, approval, and patent details, and the latest news and press releases.

Get In-Depth Knowledge on EGFR Inhibitors-Induced Skin Disorders Market Trends and Forecasts with DelveInsight @ EGFR Inhibitors-Induced Skin Disorders Treatment Market [https://www.delveinsight.com/sample-request/egfr-inhibitors-induced-skin-disorders-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

EGFR Inhibitors-Induced Skin Disorders Therapies and Companies

* LUT-014: Lutris Pharma
* HT-001: Hoth Therapeutics
* AC-701 Topical Gel 0.3%: TWi Biotechnology Inc.

EGFR Inhibitors-Induced Skin Disorders Market Outlook

The treatment of EGFR inhibitor related skin reactions is not standardized and is based on local practice and mainly derived from personal, albeit extensive, experience. Currently, there is no approved therapy specific for anti-EGFR-induced skin diseases in the US, EU4 the UK, and Japan. The off-label therapeutic options used for anti-EGFR-induced skin diseases are sunscreen, emollients and soap substitutes, antibiotics, antihistamines, topical steroids, and cosmetics. In contrast to acne vulgaris, topical antibiotic treatment with erythromycin, metronidazole, or nadifloxacin twice daily is recommended for early-stage and low-grade papulopustular skin reactions. Skin moisturizer and urea- or polidocanol-containing lotions are used to soothe. The rise in the patient pool of EGFR Inhibitors-Induced Skin Disorders is due to a hike in access to EGFR inhibitors and an increase in the incidence of EGFR mutated cancer cases, the expected launch of emerging therapies will drive the EGFR inhibitors-induced skin disorders treatment market in the forecasted period (2024-2034).

Scope of the EGFR Inhibitors-Induced Skin Disorders Market Report

- Study Period: 2020-2034

- Coverage: 7MM

- EGFR Inhibitors-Induced Skin Disorders Companies- AstraZeneca, Pfizer, Novartis Pharmaceuticals, Janssen Research & Development, Yuhan Corporation, Takeda , and many others.

- EGFR Inhibitors-Induced Skin Disorders Therapies- LUT-014, HT-001, AC-701 Topical Gel 0.3%, and others

- EGFR Inhibitors-Induced Skin Disorders Therapeutic Assessment: EGFR Inhibitors-Induced Skin Disorders current marketed and EGFR Inhibitors-Induced Skin Disorders emerging therapies

- EGFR Inhibitors-Induced Skin Disorders Market Dynamics: EGFR Inhibitors-Induced Skin Disorders market drivers and EGFR Inhibitors-Induced Skin Disorders market barriers

- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

- EGFR Inhibitors-Induced Skin Disorders Unmet Needs, KOL's views, Analyst's views, EGFR Inhibitors-Induced Skin Disorders Market Access and Reimbursement

Explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth EGFR Inhibitors-Induced Skin Disorders Market Forecast @ EGFR Inhibitors-Induced Skin Disorders Clinical Trials Assessment [https://www.delveinsight.com/sample-request/egfr-inhibitors-induced-skin-disorders-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

1. EGFR Inhibitors-Induced Skin Disorders Market Report Introduction

2. Executive Summary for EGFR Inhibitors-Induced Skin Disorders

3. SWOT analysis of EGFR Inhibitors-Induced Skin Disorders

4. EGFR Inhibitors-Induced Skin Disorders Patient Share Overview at a Glance

5. EGFR Inhibitors-Induced Skin Disorders Market Overview at a Glance

6. EGFR Inhibitors-Induced Skin Disorders Disease Background and Overview

7. EGFR Inhibitors-Induced Skin Disorders Epidemiology and Patient Population

8. Country-Specific Patient Population of EGFR Inhibitors-Induced Skin Disorders

9. EGFR Inhibitors-Induced Skin Disorders Current Treatment and Medical Practices

10. EGFR Inhibitors-Induced Skin Disorders Unmet Needs

11. EGFR Inhibitors-Induced Skin Disorders Emerging Therapies

12. EGFR Inhibitors-Induced Skin Disorders Market Outlook

13. Country-Wise EGFR Inhibitors-Induced Skin Disorders Market Analysis

14. EGFR Inhibitors-Induced Skin Disorders Market Access and Reimbursement of Therapies

15. EGFR Inhibitors-Induced Skin Disorders Market Drivers

16. EGFR Inhibitors-Induced Skin Disorders Market Barriers

17. EGFR Inhibitors-Induced Skin Disorders Appendix

18. EGFR Inhibitors-Induced Skin Disorders Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=egfr-inhibitorsinduced-skin-disorders-market-size-in-the-7mm-is-expected-to-increase-at-a-significant-cagr-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/egfr-inhibitors-induced-skin-disorders-market

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.